JENNIFER FLANNERY: Open Payments
NPI 1790040640 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,343 in 108 payments from 15 companies in 2025. Trend: 2023 $676 · 2024 $1,893 · 2025 $2,343
Food & beverage: $2,343
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $582 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 24 | $472 |
| Ardelyx, Inc. | 17 | $323 |
| GENZYME CORPORATION | 9 | $309 |
| Celltrion USA Inc. | 4 | $168 |
| Lilly USA, LLC | 2 | $125 |
| Regeneron Healthcare Solutions, Inc. | 6 | $105 |
| Aimmune Therapeutics, Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| PFIZER INC. | 3 | $45 |
Products named: XIFAXAN, DUPIXENT, IBSRELA, RINVOQ, ZYMFENTRA, ZEPBOUND, SKYRIZI, ZENPEP.
Industry payments across PA — which companies pay providers there.
